Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: 2 - What They Never Told You

Novo Nordisk Just Axed Its Deal with Hims & Hers. Should You Buy the Dip in HIMS Stock?

Hims & Hers stock tumbles as Novo Nordisk terminates Wegovy deal. BofA warns of significant further downside in the HIMS share price.

Barchart

Weight-loss jab Mounjaro helps people shed much more weight than rival – study

Mounjaro (tirzepatide) and Wegovy (semaglutide) are weight-loss medicines that make people feel fuller for longer and therefore less hungry.

The Independent UK

Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors

Novo Nordisk slashed prices on its GLP-1 obesity drugs as it launches NovoCare to gain compounded GLP-1 users as the compounding labs face deadlines to cease.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Weight loss drug Wegovy approved to treat heart disease in overweight and obese Australian patients

TGA approved new indication for semaglutide drug in December 2024, but allocation to PBS still to be decided

The Guardian - AU

Wegovy maker Novo Nordisk sponsored British pharmacies in pursuit of sales

Danish drug company gave money for Google ads to promote weight loss services and received data on web traffic and prescriptions

The Guardian - UK

Ozempic, Wegovy or Mounjaro? The battle of the weight-loss injections

As drugs emerge as vital to the Government’s anti-obesity strategy, BBC Panorama is shedding light on the pharmaceuticals industry behind them

Evening Standard

Considering taking Wegovy to lose weight? Here are the risks and benefits – and how it differs from Ozempic

The weight-loss drug Wegovy is now available in Australia.

The Conversation

Read news from The Economist, FT, and more,
with one subscription

Women advised to pair effective contraception with ‘skinny jabs’

Amid baby boom reports linked to drugs such as Wegovy and Ozempic, experts say it would be ‘wise’ to take extra precautions

The Guardian - UK

Decades-old law limits access to Wegovy for Medicaid beneficiaries

New medications like Wegovy are changing the way people lose weight and manage obesity, but many Medicaid beneficiaries can't get them.

WEKU

Danish firm behind weight-loss drug Wegovy raises profit forecast to £15.3bn

Novo Nordisk, which is now Europe’s most valuable company, also reports strong sales of diabetes drug Ozempic

The Guardian - UK

US FDA Approves Wegovy To Cut Risk Of Heart Problems

The US Food and Drug Administration has given the green light for a popular anti-obesity drug to be used to prevent serious heart conditions for the first time, in a move likely to expand insurance coverage.

International Business Times

Novo Holdings Acquires Catalent for .5 Billion, Expands Wegovy Capacity

Novo Holdings has announced its acquisition of Catalent for .5 billion, a move aimed at expanding the production capacity of Wegovy, a drug used for obe...

Top News

Obesity drug boom pushes Novo Nordisk shares to record high

Market value of Danish drugmaker behind Wegovy and Ozempic tops $500bn as demand soars

The Guardian - UK

Obesity drug Wegovy cut risk of serious heart problems by 20%, study finds

A new large study finds that the popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in certain patients

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

Novo Nordisk faces first real test as Eli Lilly wins approval for a weight loss-aiding drug

U.S. regulators signed off on Eli Lilly’s diabetes drug Zepbound, which can also be used to aid weight loss like Wegovy and Ozempic.

Fortune

Weight-loss drugs like Ozempic have so much promise a major bank is telling investors to short junk food stocks

Barclays strategists expect "disruption into a number of industries," thanks to drugs like Novo Nordisk's Ozempic and Wegovy.

The Independent UK

Wegovy weight-loss jab 'significantly' improves blood sugar in diabetics

Hailed as potential ‘game changer’ in tackling obesity, Semaglutide can also help those with type 2 diabetes

The Guardian - UK

Wegovy: the slimming drug that keeps Denmark’s economy growing

Novo Nordisk, the maker of the blockbuster obesity injection, has singlehandedly saved the country from recession

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

Novo Nordisk beats LVMH to become Europe’s most valuable company after it takes its ‘miracle’ weight loss drug Wegovy to the U.K.

The Danish pharma giant overtook French luxury conglomerate LVMH as the most valuable European company, which held the title since 2021.

The Guardian - UK

Wegovy could mean the end of obesity? That’s bad news for politicians

It has been easy to scapegoat overweight people for Britain’s collapsing health system. No wonder this new drug is being launched so cautiously, writes Zoe Williams

Evening Standard

Wegovy weight-loss jab to launch in the UK

The drug is in short supply but a proportion has been allocated to specialist NHS services

The Independent UK

NHS patients to be prescribed Wegovy weight-loss jab for first time

‘Game-changer’ injection will be prescribed via specialist NHS weight management services

The Independent UK

Patients taking blockbuster drugs like Wegovy for weight loss may face potentially deadly complications if they need surgery or other procedures that require empty stomachs for anesthesia

Fortune

A pharma company helping Elon Musk shed weight is now worth more than the entire economy of Denmark

The weight-loss and diabetes injectables have seen a surge in demand primarily in the U.S., buoying Novo Nordisk’s profits in the first half of 2023.

WEKU

Ozempic and Wegovy maker courts prominent Black leaders to get Medicare's favor

Drugmaker Novo Nordisk focuses on Black lawmakers and opinion leaders to spread the message that obesity is a chronic disease — worth treating at a cost of $1,000 or more a month.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.